Management of chronic HBV-HDV patients chronic HBV-HDV infection
Hepatitis D virus was first described by Mario Rizzeto in 1977, and it is considered chronic viral hepatitis with the poorest prognosis. Despite its discovery almost 50 years ago, progress in its diagnosis and treatment has been scarce until recent years. The approval of bulevirtide has shed some li...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:dnet:uabarcelona_::7daa7c77b34a6e2025f1960e7cb60dbd |
| Acceso en línea: | https://ddd.uab.cat/record/328311 https://dx.doi.org/urn:doi:10.1002/ueg2.12494 |
| Access Level: | acceso abierto |
| Palabra clave: | Buleviritide chronic HBV-HDV infection hepatitis B virus hepatitis D virus Interferon alpha Lonafarnib |
| Sumario: | Hepatitis D virus was first described by Mario Rizzeto in 1977, and it is considered chronic viral hepatitis with the poorest prognosis. Despite its discovery almost 50 years ago, progress in its diagnosis and treatment has been scarce until recent years. The approval of bulevirtide has shed some light for patients with Chronic Hepatitis D, although important gaps regarding its use in therapy as well as about the epidemiology and diagnosis of the disease need to be addressed. |
|---|